0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Octreotide Treatment of Acromegaly: A Randomized, Multicenter Study

Shereen Ezzat, MD; Peter J. Snyder, MD; William F. Young, MD; Louis D. Boyajy, PhD; Connie Newman, MD; Anne Klibanski, MD; Mark E. Molitch, MD; Aubrey E. Boyd, MD; Leslie Sheeler, MD; David M. Cook, MD; William B. Malarkey, MD; Ivor Jackson, MD; Mary Lee Vance, MD; Michael O. Thorner, MD; Ariel Barkan, MD; Lawrence A Frohman, MD; and Shlomo Melmed, MD
[+] Article and Author Information

Grant Support: By Sandoz Research Institute.

Requests for Reprints: Shlomo Melmed, MD, B-131, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

Current Author Addresses: Dr. Ezzat: The Wellesley Hospital, E. K. Jones Building #536, 160 Wellesley Street East, Toronto, Ontario M4Y 1J3, Canada.

Dr. Snyder: University of Pennsylvania School of Medicine, 36th St and Hamilton Walk, Philadelphia, PA 19104.

Dr. Young: Department of Medicine, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905.

Dr. Boyajy: Neuroendocrine Department, Sandoz Research Institute, Route 10, East Hanover, NJ 07936.

Dr. Newman: Department of Medicine, New York University Medical Center/Manhattan Veterans Affairs hospital, 408 First Avenue, New York, NY 10010.

Dr. Klibanski: Thyroid Unit/Department of Medicine, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114.

Dr. Molitch: Center for Endocrinology, Metabolism, and Nutrition, Northwestern University Medical School, 303 East Chicago Avenue. Chicago, IL 60611.

Dr. Boyd: Division of Endocrinology, New England Medical Center, 750 Washington Street, Boston, MA 02111.

Dr. Sheeler: Department of Endocrinology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195.

Dr. Cook: University of Oregon School of Medicine, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201.

Dr. Malarkey: Department of Medicine, Ohio State University Medical Center, N-1106 Doan Hall, Columbus, OH 43210.

Dr. Jackson: Department of Medicine, Brown University-Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903.

Drs. Vance and Thorner: Department of Medicine, University of Virginia Medical Center, Box 511, Charlottesville, VA 22908.

Dr. Barkan: Endocrinology Section, Veterans Affairs Medical Center, 2215 Fuller Road, Ann Arbor, MI 48105.

Dr. Frohman: Division of Endocrinology & Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH 45267.

Dr. Melmed: Division of Endocrinology & Metabolism, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.


Ann Intern Med. 1992;117(9):711-718. doi:10.7326/0003-4819-117-9-711
Text Size: A A A

Objective: To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.

Design: Double-blind, randomized trial.

Setting: Fourteen university-affiliated medical centers.

Patients: One hundred fifteen acromegalic patients, 70% of whom had persistent disease after pituitary surgery or radiotherapy.

Intervention: Subcutaneous octreotide, 100 µg, or placebo every 8 hours for 4 weeks. Four weeks after the end of treatment, patients were randomized to receive 100 or 250 µg octreotide subcutaneously every 8 hours for 6 months.

Results: After 2 weeks of treatment, a single 100-µg injection reduced mean serum growth hormone (GH) to 30% of the pretreatment concentration within 2 hours. The integrated mean GH level was reduced over 8 hours from 39 ± 11 µg/L to 9 ± 2 µg/L (P < 0.001). Mean plasma insulin-like growth factor-1 (IGF-1) was reduced from 5100 µ 400 U/L to 2400 ± 400 U/L (P < 0.001). After 6 months, the mean GH was reduced from 39 ± 13 to 15 ± 4 µg/L by 300 µg of octreotide and from 29 ± 5 µg/L to 9 ± 2 µg/L by 750 µg of octreotide daily. The mean IGF-1 concentration was suppressed to 2100 ± 300 and 2500 ± 400 U/L after 300 and 750 µg octreotide, respectively. Integrated mean GH levels were reduced to less than 5 µg/L in 53% (95% Cl, 39% to 67%) and 49% (Cl, 35% to 63%), and IGF-1 levels were normal in 68% (Cl, 54% to 82%) and 55% (Cl, 40% to 70%) of patients receiving low- and high-dose octreotide, respectively. A substantial decrease in headache, amount of perspiration, joint pain, and finger circumference occurred in two thirds of the patients. The pituitary size was reduced in 19% (Cl, 5% to 33%) and 37% (Cl, 22% to 52%) of patients receiving 6 months of low- and high-dose octreotide, respectively. Ten percent and 13% of patients in each treatment group developed transient diarrhea; 10% and 14%, biliary sludge; and 6% and 18%, cholelithiasis, respectively.

Conclusion: Octreotide effectively decreased GH and IGF-1 concentrations in 53% and 68% of patients, respectively. The higher dose resulted in increased frequency of tumor shrinkage but added no biochemical or clinical benefit.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Using Growth Hormone Levels to Detect Macroadenoma in Patients with Acromegaly. Endocrinol Metab (Seoul) Published online May 27, 2014.;
Lanreotide autogel in acromegaly - a decade on. Expert Opin Pharmacother Published online Oct 11, 2014.;
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)